Showing 1 - 10 of 11
The Kyoto Protocol is an important and necessary step toward protecting the global environment. However, analysis reveals problems that could hamper the effectiveness of this treaty. Technical deficiencies, ambiguities, and inconsistencies exist in the legal text. In addition, from the Canadian...
Persistent link: https://www.econbiz.de/10005773989
Persistent link: https://www.econbiz.de/10005431980
We analyze the effects of various kinds of demand- and supply-side incentives in the context of a model in which patients and doctors must decide not only on an aggregate quantity of health services to use in treating various kinds of illness, but also have a choice between different kinds of...
Persistent link: https://www.econbiz.de/10005518260
Persistent link: https://www.econbiz.de/10005424477
No abstract received.
Persistent link: https://www.econbiz.de/10005047211
In a theoretical model, we analyze the effects of various kinds of demand- and supply-side incentives in the context of a model in which patients and doctors must decide not only on an aggregate quantity of health services to use in treating various kinds of illness, but also have a choice...
Persistent link: https://www.econbiz.de/10005100661
Economic evaluation in health care often involves cost-utility analysis (CUA), a method based on the cost-effectiveness criterion of dollars per Quality-Adjusted Life Year (QALY), where the quality adjustement factors for years lived in ill health are established through answers to...
Persistent link: https://www.econbiz.de/10005812606
Persistent link: https://www.econbiz.de/10008484910
The purpose of the present paper is to show that much of the literature on health economics and on the international experience with different forms of health system organization can be interpreted as supporting the idea that reliance on an unregulated market mechanism for organizing the...
Persistent link: https://www.econbiz.de/10008484922
We build a model of pharmaceutical markets in the light of a patent race among competing firms. The incentive for R&D is the patent on either the breakthrough or the me-too drug. A feature of our model that has not been analyzed before is the prevalence of insurance in developed countries as...
Persistent link: https://www.econbiz.de/10005157515